Sign in
STLN Stock Price, Chart, Stats & News
Starling Oncology, Inc.
Save
Starling Oncology, Inc. (STLN) does not currently pay a dividend.
644.89M
Market cap
–
Current P/E
–
Forward P/E
STLN chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 30.57% |
Operating margin | -5.44% |
Pretax margin | -8.47% |
Net margin | -7.84% |
Effective tax rate | 7.29% |
ROA | -11.75% |
ROE | -72.21% |
D/E | 2.33x |
Interest coverage ratio | -1.90x |
STLN valuation
P/E | – |
P/S | 0.02x |
P/B | 0.11x |
P/CF | -0.25x |
P/FCF | -0.20x |
P/OCF | -0.25x |
PEG | -0.00x |
EV multiple | -14.90x |
About
Starling Oncology, Inc., formerly The Oncology Institute, is a value-based oncology company advancing cancer care in the community setting. Founded in 2007, the company offers cutting-edge, evidence-based cancer treatments, including clinical trials and transfusions, to a large patient population. It operates as an integrated oncology platform serving patients, providers, and health plans across multiple markets with a focus on delivering high-quality, patient-centered care.
Similar securities
Based on sector and market capitalization
Report issue